Catalyst Pharmaceuticals [CPRX] — Trade Construction
Framework: Criteria, 2026-07-29. No position verdict is issued.
1. Liquidity Criteria — BINDING — FAIL
No trade in CPRX is constructible at any size, in any vehicle, at any price.
| Test | Evidence |
|---|---|
| Can the common stock be bought? | No. Last trade 2026-07-14 19:59:54 UTC, $31.49 (Alpaca SIP trades/latest). No daily bar exists after 2026-07-14 on any feed. |
| Is it listed? | No. Form 25-NSE filed 2026-07-15 (Nasdaq delisting notification). |
| Is it a registrant? | No. Form 15-12G filed 2026-07-24; Exchange Act reporting obligations suspended. |
| Is there an options chain? | No chain to pull. The Liquidity Criteria requires the actual chain — open interest and quoted size for specific strikes and expiries — before any structure is proposed. There is no underlying. No structure is proposed. |
| Does a residual claim exist? | No. Every share outstanding at the effective time was cancelled and converted into the right to receive $31.50 in cash (8-K 2026-07-16). |
This is the only unambiguous FAIL in the Criteria block and it is dispositive on its own. Position size: zero, structurally, not by choice.
The stale quote, and why it is dangerous rather than merely wrong
Alpaca's quotes/latest still returns bid $31.48 / ask $31.51, size 200 × 200. That quote is timestamped
2026-07-14T20:19:55Z and has not updated in ten sessions. An execution system that reads a "latest quote"
without checking its timestamp would see a tight two-cent market in size and conclude the name is liquid.
Proposed control, generalisable beyond this name: any quote or trade used for sizing or execution must carry a staleness assertion — reject if the timestamp is more than N sessions old. This is a one-line check against a field the API already returns, and it is currently absent.
2. What the trade would have been, pre-deal
Recorded so the counterfactual is on file and can be scored, not because it is actionable.
Underwriting date: 2026-04-22, the last unaffected close, $25.94.
| Direction | Long, small |
| Thesis | FIRDAPSE compounding at ~18% behind a January-2035 patent wall, with a dated, contractual gross-margin step (upstream royalty 18.5% → 6.0%, January 2026) and an AGAMREE launch curve still growing 67% YoY — against a collapsing acquired asset (FYCOMPA) and an unproven capital-redeployment engine sitting on $755.9m of cash. |
| 12-month target | $32.15 (own-history median EV/EBIT 11.26x on guided FY26 revenue) |
| Upside to entry | +24.0% |
| Entry multiple | 10.26x TTM EBIT — 41st percentile of the name's own six-year history |
| Bear case | −13% to −20% (see Research §8), named cause: acquisition-engine failure with FYCOMPA as the demonstrated precedent |
| Vehicle | Common stock only. No options structure could be justified without the chain, and none was pulled. |
| Sizing | Small. Not on volatility — on the fact that 61.5% of the demonstrated growth was acquired and the forward guided rate was +4.4% to +9.5%. The screen's inverse-vol logic would have sized this large; the correct input is the growth decomposition, not the vol. |
Realised: $31.50 cash on 2026-07-15, +21.4% from the unaffected close, in 84 days.
3. Position and book implications
Nothing is added to the book. No entry, no exit, no sizing, no ledger entry in
trade_recommendations.jsonl — that ledger is for specific options trade recommendations, and no trade was or
could be recommended.
One thing should be added: a screen-hygiene control. See CPRX_Research.md §10. The five items there are
the deliverable of this memo that has value going forward; the name itself has none.
4. Risk management
Not applicable. There is no position, no invalidation level, no drawdown ladder and no de-gross trigger, because there is no exposure and none can be established.